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Limited clinical data are available to assess whether the sequencing of cyclophosphamide (Cy) and total body
irradiation (TBI) changes outcomes. We evaluated the sequence in 1769 (CyTBI, n ¼ 948; TBICy, n ¼ 821)
recipients of related or unrelated hematopoietic cell transplantation who received TBI (1200 to 1500 cGY) for
acute leukemia from 2003 to 2010. The 2 cohorts were comparable for median age, performance score, type of
leukemia, ﬁrst complete remission, Philadelphia chromosomeepositive acute lymphoblastic leukemia, HLA-
matched siblings, stem cell source, antithymocyte globulin use, TBI dose, and type of graft-versus-host dis-
ease (GVHD) prophylaxis. The sequence of TBI did not signiﬁcantly affect transplantation-related mortality
(24% versus 23% at 3 years, P ¼ .67; relative risk, 1.01; P¼ .91), leukemia relapse (27% versus 29% at 3 years, P ¼
.34; relative risk, .89, P ¼ .18), leukemia-free survival (49% versus 48% at 3 years, P ¼ .27; relative risk, .93; P ¼
.29), chronic GVHD (45% versus 47% at 1 year, P ¼ .39; relative risk, .9; P ¼ .11), or overall survival (53% versus
52% at 3 years, P ¼ .62; relative risk, .96; P ¼ .57) for CyTBI and TBICy, respectively. Corresponding cumulative
incidences of sinusoidal obstruction syndrome were 4% and 6% at 100 days (P ¼ .08), respectively. This study
demonstrates that the sequence of Cy and TBI does not impact transplantation outcomes and complications in
patients with acute leukemia undergoing hematopoietic cell transplantation with myeloablative conditioning.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTIONdgments on page 1256.




ty for Blood and Marrow Transplantation.Controversy concerning the optimal conditioning
regimen and sequence of modalities for patients with he-
matologic malignancies still persists. The optimal regimen
would maximize tumor cell kill and minimize toxicities.
Cyclophosphamide (Cy) and total body irradiation (TBI) have
J.L. Holter-Chakrabarty et al. / Biol Blood Marrow Transplant 21 (2015) 1251e12571252been used in combination as a preparative regimen for high-
risk hematologic malignancies for several decades. Animal
preclinical data in the early 1990s showed that Cy given 24
hours after TBI (TBICy) caused less lung damage but more
bone marrow damage in the murine model [1,2]. Lowenthal
et al. showed that the reverse, or CyTBI, offers an improved
antileukemic effect, compared with TBICy, in mice with B cell
leukemia/lymphoma [3]. The optimal sequence of these
agents in the preparative regimen and the associated impact
on clinical outcomes, such as transplantation-related mor-
tality (TRM) and leukemia relapse, has not been systemati-
cally studied to date.
Synergism between chemotherapy and radiation therapy
exists. In early studies, TBI was used solely as the condi-
tioning regimen [4]. The goal of TBI is to obliterate the host
marrow, deplete residual leukemia, and allow for donor
marrow cells to repopulate through immune-ablation. TBI
has high efﬁcacy; however, there is controversy over the
optimal dose, as higher doses have been related to increased
incidence of graft-versus-host disease (GVHD) and mortality,
thought to be triggered by radiation-related tissue damage
[5]. A TBI-only regimen was less effective at lower doses of
TBI and more toxic at higher doses of TBI (1400 to 2000 cGy)
[6]. Cy was later added to the regimen, permitting lower TBI
doses to be used, thereby decreasing the incidence of pul-
monary toxicity while maintaining stable rates of leukemia
relapse and immune-ablation [7]. The standard regimen for
adults used for disease ablation and immunosuppression in
patients with leukemia was established in the early 1970s
and is Cy 60 mg/kg/day for 2 days for adults (4 days for
children) followed by 3 to 4 days of TBI [7]. A number of
modiﬁcations to this regimen have been introduced to
improve the rates of engraftment and reduce the relapse rate
and radiation complications [8,9]. Another rationale for
changing the sequence in the conditioning regimens was
related to Cy-induced emesis, which could affect the sched-
uling of subsequent TBI. Despite evidence that CyTBI is a
good choice of myeloablative regimen, no overall consensus
on timing of TBI and Cy has been investigated in large series.
This is a common clinical question in cases of conﬂicting
schedules of irradiation treatment days and arrival or avail-
ability of a stem cell product for transplantation. The goal of
this study was to compare CyTBI to TBICy in terms of the
incidence of GVHD, leukemia relapse, and incidence of si-
nusoidal obstruction syndrome (SOS).METHODS
Data Source
The Center for International Blood and Marrow Transplant Research
(CIBMTR) is a voluntary working group of more than 450 transplantation
centers worldwide that contribute detailed data on consecutive hemato-
poietic cell transplantations to a statistical center located at the Medical
College of Wisconsin in Milwaukee and the National Marrow Donor Pro-
gram Coordinating Center in Minneapolis. Participating centers are required
to report all transplantations consecutively; compliance is monitored by
onsite audits. The CIMBTR maintains an extensive database of detailed pa-
tient-, transplantation-, and disease-related information, and prospectively
collects data longitudinally with yearly follow-ups. Observational studies
conducted by the CIBMTR are performed in compliance with Health Insur-
ance Portability and Accountability Act regulations as a public health au-
thority and also in compliance with all applicable federal regulations
pertaining to the protection of human research participants, as determined
by a continuous review by the institutional review boards of National
Marrow Donor Program and the Medical College of Wisconsin [10].Patients
Patients were younger than 60 years, received hematopoietic cell
transplantation with Cy and TBI with myeloablative doses of 1200 to 1500cGY for treatment of acute leukemia in ﬁrst or second completemorphologic
remission from 2003 to 2010, and reported to the CIBMTR. Patients who
received umbilical cord blood grafts, haploidentical or other HLA-
mismatched donors, or ex vivo T cell depletion were excluded. Median
follow-up of cohort was 56 months and the completeness index [11] (the
observed/the expected follow-up) for a 3-year analysis was 88%. Eligible
patients were separated according to the sequence of agents into CyTBI and
TBICy groups based on the reported dates of administration of Cy and TBI.
Outcome
The conditioning regimen sequence was compared according to overall
survival (OS), leukemia-free survival (LFS), TRM, leukemia relapse, GVHD,
and SOS. Events of GVHD and SOS were deﬁned by transplantation centers.
GVHD data included date of onset, organ involvement, and maximum grade.
SOS data includes differential diagnosis and supporting clinical and diag-
nostic information. OS was deﬁned as death by any cause and patients were
censored at time of last follow-up. Leukemia relapse or death was recorded
as the event for the LFS outcome. TRM was deﬁned as any death in the
absence of prior leukemia relapse. GVHD was analyzed as grades III and IV
and II to IV acute (aGVHD) according tomodiﬁed Gluksberg [12] and chronic
GVHD (cGVHD).
Statistical Analysis
Eligible patients were separated into 2 cohorts according to the
sequence of TBI and Cy (CyTBI and TBICy), deﬁned according to date of
initiation of each component of the conditioning regimen. Selected variables
were described for both cohorts, continuous variables were compared by
Kruskall Wallis test, and categorical variables by chi-square test to assess
signiﬁcant differences (deﬁned as P value < .05).
Survival outcomes including OS and LFS were computed using Kaplan-
Meier and comparison was done with log rank test. For leukemia relapse,
TRM and GVHD outcomes, and SOS incidence, cumulative incidence was
used to account for competing risks. Cox proportional hazards regression
models for overall mortality, treatment failure (inverse of LFS), relapse and
TRM were built using a forward selection approach forcing the main effect
covariates (TBICy versus CyTBI) on all outcomes. The covariates analyzed
include age, gender, performance score, donor-recipient gender, disease and
disease status, cytogenetic risk stratiﬁcation (for acute myeloid leukemia
(AML) according to the Southwest Oncology Group/Eastern Cooperative
Oncology Group classiﬁcation [13]: favorable, intermediate, poor, or un-
known; for acute lymphoid leukemia (ALL): presence of Philadelphia
chromosome [Phþ], Ph negative and Ph status unknown), year of trans-
plantation, donor type (sibling, well matched, and partially matched unre-
lated donor) [14], dose of TBI (12 Gy versus 13 Gy), donor recipient
cytomegalovirus status, graft source, in vivo T cell depletion. Disease status
and cytogenetic assessments were performed at the transplantation center
and reported to the CIBMTR. The ﬁnal model included all covariates signif-
icantly associated with the outcome (P < .05) and the main effect. Test for
proportional hazards was included in case of nonproportional hazards
during the study period and test for interactions was done between the
main effect covariates and all signiﬁcant covariates in each model.
RESULTS
Demographics
A total of 948 patients received CyTBI and 821 received
TBICy. The 2 cohorts were comparable for patient-, disease-,
and transplantation-related characteristics (Table 1) with the
exception of age and Cy dose. The median age was 33 in the
CyTBI group and 35 in the TBICy group (P < .01). The median
Cy dose was 108 mg/kg in the CyTBI group and 115 mg/kg in
the TBICy group (P ¼ .01). The median interval between
starting TBI and Cy was 2 and 4 days for CyTBI and TBICy,
respectively.
GVHD
Cumulative incidences of grade II to IV aGVHD at day 100
were 39% (95% conﬁdence interval [CI], 35% to 42%) and
45% (95% CI, 41% to 48%; P ¼ .01), and of grades III and IV
aGVHD were 16% (95% CI, 13% to 18%) and 15% (95% CI, 12% to
17%; P ¼ .60) for CyTBI and TBICy, respectively (Figure 1).
Multivariate analysis comparing CyTBI to TBICy demon-
strated a relative risk for grades II to IV aGVHD of .87 (95% CI,
.75 to 1.00; P ¼ .05) and for grades III and IV aGVHD of 1.09
Table 1
Characteristic of AML and ALL Patients who Received Allogeneic Hemato-
poietic Cell Transplantationwith TBI and Cy Conditioning Regimen between
2003 and 2010, According to Sequence of Administration
Characteristics of Patients TBICy CyTBI P
Value
No. of patients 821 948
No. of centers 100 114
Age, median (range), yr 33 (2-60) 35 (2-60) <.01
0-9 64 (8) 61 (6) <.01
10-19 147 (18) 114 (12)
20-29 157 (19) 212 (22)
30-39 168 (20) 172 (18)
40-49 180 (22) 224 (24)
50-59 105 (13) 165 (17)
Sex .63
Male 458 (56) 518 (55)
Female 363 (44) 430 (45)
Race .01
Caucasian 663 (81) 827 (87)
African-American 30 (4) 31 (3)
Asian 76 (9) 49 (5)
Paciﬁc islander 2 (<1) 1 (<1)
Native American 5 (<1) 4 (<1)
Other 20 (2) 14 (1)
Unknown 25 (3) 22 (2)
Performance score .08
<90% 164 (20) 223 (24)
90% 608 (74) 656 (69)
Unknown 49 (6) 69 (7)
Disease .09
AML 456 (56) 489 (52)
ALL 365 (44) 459 (48)
AML/ALL disease status before
transplantation
.82
First CR 529 (64) 606 (64)
Second CR 292 (36) 342 (36)
AML cytogenetics .55
Favorable 36 (8) 44 (9)
Intermediate 187 (41) 187 (38)
Poor 105 (23) 129 (26)
Unknown 128 (28) 129 (26)
ALL Phþ .77
No 131 (36) 154 (34)
Yes 90 (25) 115 (25)
Unknown 144 (39) 190 (41)
Donor/recipient HLA match .01
HLA-identical sibling 281 (34) 329 (35)
Well-matched URD 346 (42) 450 (47)
Partially matched URD 136 (17) 125 (13)
URD-HLA matching
unavailable
58 (7) 44 (5)
Graft type .12
BM 305 (37) 319 (34)
PB 516 (63) 629 (66)
Donor/recipient sex match .62
M-M 291 (35) 333 (35)
F-M 165 (20) 180 (19)
M-F 194 (24) 241 (25)
F-F 168 (20) 186 (20)




þ/þ 224 (27) 272 (29)
þ/ 96 (12) 122 (13)
/þ 203 (25) 250 (26)
/ 266 (32) 264 (28)
Unknown 32 (4) 40 (4)
Total Cy dose,
median (range), mg/kg
115 (<1-470) 108 (<1-486) .01
<55 mg/kg 33 (4) 58 (6) .02
55-96 mg/kg 166 (20) 234 (25)
97-120 mg/kg 474 (58) 482 (51)
121-135 mg/kg 52 (6) 70 (7)
>135 mg/kg 28 (3) 39 (4)




Characteristics of Patients TBICy CyTBI P
Value
TBI dose .51
1200-1300 cGy 514 (63) 579 (61)
1320-1500 cGy 307 (37) 369 (39)
TBI fractionated .21
No 1 (<1) 4 (<1)
Yes 820 (99) 942 (99)
Unknown 0 2 (<1)
CNS boost given .40
No 768 (94) 891 (94)
Yes 52 (6) 53 (6)
Unknown 1 (<1) 4 (<1)
Interval between TBI and Cy, d 4 (2-7) 2 (2-6) <.001
Year of transplantation .08
2003 67 (8) 78 (8)
2004 130 (16) 167 (18)
2005 118 (14) 173 (18)
2006 137 (17) 142 (15)
2007 107 (13) 110 (12)
2008 103 (13) 84 (9)
2009 85 (10) 98 (10)
2010 74 (9) 96 (10)
Use of ATG .10
ATG alone 108 (13) 101 (11)
No ATG 713 (87) 847 (89)
GVHD prophylaxis .12
Tacro þ MMF  others 57 (7) 70 (7)
Tacro þ MTX  others 371 (45) 409 (43)
Tacro  others 42 (5) 76 (8)
CSA þ MMF  others 11 (1) 5 (<1)
CSA þ MTX  others 317 (39) 364 (38)
CSA  others 15 (2) 13 (1)
Other GVHD prophylaxis 8 (<1) 11 (1)
Follow-up of survivors, median
(range), mo
57 (3-100) 56 (3-100)
CR indicates complete remission; URD, unrelated donor; BM, bone marrow;
PB, peripheral blood; M, male; F, female; CMV, cytomegalovirus; CNS,
central nervous system; ATG, antithymocyte globulins; Tacro, tacrolimus;
MMF, mycophenolate mofetil; MTX, methotrexate; CSA, cyclosporine.
J.L. Holter-Chakrabarty et al. / Biol Blood Marrow Transplant 21 (2015) 1251e1257 1253(95% CI, .86 to 1.38; P ¼ .50). Other covariates associated with
grades II to IV aGVHD were donor-recipient gender combi-
nations, donor type, and graft source (Supplementary
Table A). Donor type and year of transplantation were asso-
ciated with grades III and IV aGVHD.
The cumulative incidences of cGVHD at 1 year were 45%
(95% CI, 41% to 48%) and 47% (95% CI, 43% to 50%; P ¼ .39)
(Figure 1). Multivariate analysis of cGVHD the relative risk of
CyTBI was .9 (95% CI, .79 to 1.03; P ¼ .11). Other covariates
associated with cGVHD were donor recipient gender match,
donor type, and graft source.Leukemia Relapse and TRM
The cumulative incidences of leukemia relapse at 3 years
were 27% (95% CI, 24% to 30%) and 29% (95% CI, 26% to 33%;
P ¼ .34) for CyTBI and TBICy, respectively (Figure 2). Corre-
sponding cumulative incidences for TRM at 3 years were 24%
(95% CI, 21% to 27%) and 23% (95% CI, 20% to 26%; P ¼ .67).
Multivariate analyses for leukemia relapse and TRM with
associated covariates are shown in Table 2.SOS
Cumulative incidences for SOS at 100 days were 4% (95%
CI, 3% to 6%) and 6% (95% CI, 4% to 8%; P¼ .08) with CyTBI and
TBICy, respectively.
Figure 1. Cumulative incidences of II to IV (A) and III and IV (B) acute GVHD, and chronic GVHD (C) comparing CyTBI with TBICy before allogeneic transplantation for
acute leukemia.
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Three-year probabilities of LFS were 49% (95% CI, 46% to
52%) and 48% (95% CI, 44% to 51%; P ¼ .34) for CyTBI and
TBICy, respectively (Figure 2). Corresponding 3-year proba-
bilities of OS were 53% (95% CI, 50% to 57%) and 52% (95% CI,
49% to 56%; P ¼ .48). Multivariate analyses for treatment
failure (1-LFS) and overall mortality with associated cova-
riates are shown in Table 2. OS by different subset of children,
adults, and patients with ALL and AML are shown in Figure 3.
Causes of Death
There was a wide range of causes of death for patients in
each group, with the most common causes being leukemiaFigure 2. Cumulative incidence of transplantation-related mortality (A), cumulative i
probability of overall survival (D) comparing CyTBI with TBICy before allogeneic tranrelapse, infection, GVHD, and pulmonary failure. Causes of
death were comparable between both treatment groups
(Supplementary Table B).
DISCUSSION
This large retrospective analysis study compared the
sequence of TBI and Cy in the myeloablative conditioning
intensity setting for acute leukemia. Transplantation out-
comes were generally similar regardless of the sequence of
TBI, with exception of grades II to IV aGVHD. All the out-
comes were similar when separating the cohort by disease
(AML and ALL) and by patient populations (children and
adults).ncidence of leukemia relapse (B), probability of leukemia-free survival (C), and
splantation for leukemia.
Table 2
Multivariate Analysis of TRM, Leukemia Relapse, Treatment Failure, and
Overall Mortality Comparing CyTBI to TBICy and Additional Covariates
Associated with Each Outcome
TRM n RR (95% CI) P Value
Main effect .91*
TBI/Cy 817 1.00 e
Cy/TBI 939 1.01 (.84-1.23)
Other covariates
Age <.0001*
0-9 124 1.00 e
10-19 260 2.49 (1.21-5.14) .013
20-29 364 3.02 (1.57-5.83) .0010
30-39 337 4.27 (2.21-8.24) <.0001
40-49 401 5.01 (2.61-9.62) <.0001
50-59 270 6.09 (3.15-11.80) <.0001
Donor-recipient sex match <.0001*
M-M 621 1.00 e
F-M 343 1.40 (1.09-1.80) .0088
M-F 433 .66 (.50-.87) .0028
F-F 348 1.18 (.91-1.51) .21
Performance score .0025*
<90% 383 1.00 e
90%-100% 1256 .70 (.56-.87) .0012
Unknown 117 .96 (.65-1.43) .85
Donor type <.0001*
HLA-identical sibling 607 1.00 e
Well-matched URD 786 1.53 (1.22-1.94) .0003
Partially matched URD 261 2.62 (1.99-3.44) <.0001
URD-HLA match missing 102 1.13 (.71-1.81) .60
Leukemia relapse
Main effect .18*
TBI/Cy 817 1.00 e
Cy/TBI 939 .89 (.75-1.06) .18
Other covariates
Cytogenetics <.0001*
AML intermediate 374 1.00 e
AML favorable 80 .14 (.05-.31) <.0001
AML unfavorable 234 1.61 (1.20-2.16) .001
AML unknown 256 1.08 (.79-1.47) .22
ALL Ph neg 285 1.16 (.86-1.56) .34
ALL Phþ 205 1.20 (.85-1.68) .30




First CR 1125 1.00 e
Second CR 631 1.34 (1.12-1.61) .0016
Treatment failure
Main effect 817 .29*
TBI/Cy 939 1.00 e
Cy/TBI .93 (.82-1.06) .29
Other covariates
Age <.0001*
0-9 124 1.00 e
10-19 260 1.52 (1.07-2.15) .020
20-29 364 1.54 (1.12-2.11) .0072
30-39 337 1.90 (1.37-2.62) .0001
40-49 401 1.98 (1.43-2.74) <.0001
50-59 270 2.48 (1.78-3.47) <.0001
Donor-recipient sex match .0005*
M-M 621 1.00 e
F-M 343 1.14 (.95-1.36) .15
M-F 433 .77 (.65-.92) .0044
F-F 348 1.05 (.88-1.25) .62
Performance score .0007*
<90% 383 1.00 e
90%-100% 1256 .78 (.67-.91) .0015
Unknown 117 1.08 (.82-1.40) .60
Cytogenetics .0012
AML intermediate 374 1.00 e
AML favorable 80 .51 (.34-.79) .002
AML unfavorable 234 1.26 (1.01-1.58) .04
AML unknown 256 1.10 (.88-1.37) .40
ALL Ph neg 285 1.20 (.96-1.51) .10
ALL Phþ 205 1.31 (1.03-1.67) .03








First CR 1125 1.00 e
Second CR 631 1.22 (1.05-1.40) .0081
Donor type .0007*
HLA-identical sibling 607 1.00 e
Well-matched URD 786 1.15 (.99-1.35) .070
Partially matched URD 261 1.45 (1.89-1.76) .0002
URD-HLA match missing 102 .84 (.60-1.69) .29
Overall mortality
Main effect .57*
TBI/Cy 821 1.00 e
Cy/TBI 948 .96 (.84-1.10) .57
Other covariates
Age <.0001*
0-9 125 1.00 e
10-19 261 1.51 (1.05-2.19) .027
20-29 369 1.65 (1.19-2.28) .0028
30-39 340 2.05 (1.46-2.87) <.0001
40-49 404 2.17 (1.54-3.04) <.0001
50-59 270 2.84 (2.01-4.02) <.0001
Donor-recipient sex match .0002*
M-M 624 1.00 e
F-M 345 1.16 (.97-1.39) .11
M-F 435 .76 (.63-.91) .0035
F-F 354 1.05 (.87-1.26) .61
Performance score .0011*
<90% 387 1.00 e
90%-100% 1264 .76 (.65-.89) .0008




First CR 1135 1.00 e
Second CR 634 1.26 (1.09-1.46) .0022
Donor type <.0001*
HLA-identical sibling 610 1.00 e
Well-matched URD 796 1.13 (.96-1.33) .13
Partially matched URD 261 1.57 (1.29-1.92) <.0001
URD-HLA match missing 102 .83 (.58-1.18) .30
Cytogenetics .0023*
AML intermediate 374 1.00 e
AML favorable 80 .56 (.37-.86) .009
AML unfavorable 234 1.35 (1.07-1.71) .012
AML unknown 256 1.10 (.87-1.38) .44
ALL Ph-neg 285 1.26 (1.00-1.59) .048
ALL Phþ 205 1.26 (.98-1.63) .068
ALL Ph- unknown 334 1.20 (.96-1.51) .10
RR indicates relative risk.
* Overall P value.
J.L. Holter-Chakrabarty et al. / Biol Blood Marrow Transplant 21 (2015) 1251e1257 1255A study by McDonald et al. linked circulating cyclophos-
phamide metabolites to liver dysfunction during TBI-based
transplantation [15]. The metabolism of Cy was found to be
highly variable, and increased levels of 1 of the metabolites,
carboxyethylephosphoramide mustard, was correlated with
higher rates of SOS and nonrelapse mortality [15]. Subse-
quently, a phase II trial investigated the effect of a person-
alized dosing scheme for each patient according to Cy
pharmacokinetics [16]. The trial concluded that a personal-
ized dosing system led to lower peak bilirubin levels and
acute kidney injury; however, nonrelapse and OS rates were
similar to controls [16]. These studies demonstrate a vari-
ability of Cy exposure using a standard regimen and a com-
mon protocol. Altering the sequence of speciﬁc agents may
increase the variability of Cy metabolism and deserves to be
speciﬁcally tested.
The exact timing between each component of the con-
ditioning regimen may also inﬂuence toxicity and trans-
plantation outcomes. Hassan et al. compared outcomes
Figure 3. Overall survival among (A) adults patients, (B) children, (C) patients with acute lymphoid leukemia, and (D) with acute myeloid leukemia according to the
sequence of cyclophosphamide and total body irradiation as part of a myeloablative conditioning before allogeneic hematopoietic cell transplantation.
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and demonstrated that shorter intervals (<24 hours) were
associated to higher exposure to Cy and, consequently, more
toxicities [17]. In preclinical studies, shorter intervals be-
tween irradiation and chemotherapy were also associated
with higher irradiation-induced tissue damage [18-19]. The
present study could only address the sequence of agents, as
only the date of initiation of each agent was available. The
interval of initiation of each agent was different between the
groups, as TBI is usually administered over a 3-day period
and Cy over a 2-day period. Additionally, the interval distri-
bution in both groups was narrow; thus, the interval be-
tween the ﬁrst days of each agent is closely related to the
sequence of agents.
Enhanced toxicity from TBI exposure to Cy metabolites
could also theoretically contribute to aGVHD. When
analyzing the incidence of aGVHD in both groups, we found
that grade II to IV GVHD at 100 days after transplantationwas
signiﬁcantly less in the CyTBI group. This should be inter-
preted with caution because the multivariate analysis
showed borderline effect and there was no difference be-
tween the 2 approaches on grades III and IV aGVHD. Addi-
tionally, the dose of TBI was evaluated and it was not
associated with the development of GVHD or any other
outcomes analyzed.
We also show that the speciﬁc type of acute leukemia is
not a factor in choosing a conditioning sequence. Previous
studies have shown that differences exist in the preparative
regimens for AML versus ALL. The optimal exact dosing of TBI
has not been established; however, total doses of >13 Gy
were associated with improved LFS, relapse, and mortality in
ALL patients in second complete remission [20]. In contrast,
Clift et al. were able to show decreased relapse but increased
mortality in AML patients treated with higher doses of TBI
[5].
Because our analysis is retrospective, it does have limi-
tations, including the reason why 1 conditioning regimen
sequence was chosen over the other. The speciﬁc sequencewas not restricted to a number of transplantation centers and
the majority of centers reported both sequences. This
observation likely reﬂects practice, as changes in the
sequence of agents are done to accommodate trans-
plantation schedule and other activities during the timing of
transplantation. Although ideally this question of the timing
of preparative components would be answered in a ran-
domized prospective trial, our data would support equipoise
for these decisions at this juncture.
This large cohort study demonstrates that the sequence of
Cy and TBI does not affect transplantation outcomes and
survival in patients with acute leukemia undergoing mye-
loablative transplantation in terms of toxicity or anti-
leukemia beneﬁt. TBICy may offer an advantage for a shorter
hospitalization because of possible TBI delivery in the
outpatient setting. This could potentially reduce the psy-
chological distress associated with prolonged hospitaliza-
tion. Furthermore, the apparent lack of difference in
outcomes on an exact sequence of these 2 conditioning
regimen agents provides ﬂexibility for transplantation
planning.
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